ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CODX Co Diagnostics Inc

1.1299
0.0499 (4.62%)
25 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Co Diagnostics Inc NASDAQ:CODX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0499 4.62% 1.1299 1.05 1.13 1.10 1.02 1.07 76,178 00:06:39

Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast

25/04/2024 2:30pm

PR Newswire (US)


Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more Co Diagnostics Charts.

SALT LAKE CITY, April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

(PRNewsfoto/Co-Diagnostics)

The conference call and webcast will be available via:

Webcast: ir.codiagnostics.com on the Events & Webcasts page

Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-first-quarter-2024-earnings-release-date-and-webcast-302125958.html

SOURCE Co-Diagnostics

Copyright 2024 PR Newswire

1 Year Co Diagnostics Chart

1 Year Co Diagnostics Chart

1 Month Co Diagnostics Chart

1 Month Co Diagnostics Chart

Your Recent History

Delayed Upgrade Clock